177Lu-NBC-02

N/A

Report date: 2025/10/20 17:51:43

Base Information

Drug Name177Lu-NBC-02

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent

Mechanisms of ActionAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGeneQuantum Healthcare (Suzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGeneQuantum Healthcare (Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A